-
Efficacy and Safety of Clascoterone Cream 1% for Acne Are Independent of Age and Sex
Acne vulgaris is an inflammatory skin condition affecting adolescents and adults of both sexes. Clascoterone cream 1% is indicated for the topical treatment of acne vulgaris in patients ≥12 years of age based on the results of two Phase 3 trials (NCT02608450 and NCT02608476). This post hoc analysis evaluated the efficacy and safety of clascoterone… →
-
Real-Time Face Tracking: OpenCV Control of a UR Robot
Picture an industrial robot that doesn’t wait for button presses or predefined programs, but instead reacts instantly to your presence. As you move, the robot’s tool gently adjusts its position, tracking your face in real time and responding with smooth, deliberate motion. This kind of interaction, where vision directly drives robotic behavior, highlights how computer… →
-
Functional capacity and quality of life after telerehabilitation in post-tuberculosis lung disease: a randomized controlled trial
CONCLUSIONS: Our findings suggest that telerehabilitation is an effective approach for enhancing physical function and QoL in patients with PTLD. →
-
Four Key Roles ‘Elders’ Offer Their Organizations
Carolyn Geason-Beissel/MIT SMR | Getty Images Imagine a world where organizations don’t just ask, “How do we attract young talent?” but also, “What do people who’ve managed multiple economic cycles think?” What if we thought of older workers as being in a distinct career stage, where their perspectives and continuity were recognized as especially valuable?… →
-
Bucking the Party Line May Not Be as Perilous as People Think
Imagine you’re a Democrat who’s begun questioning your party’s position on immigration, or a Republican rethinking the party line on gun control. In today’s highly polarized political climate, the thought of voicing that dissent to fellow partisans can feel socially risky—an act that might brand you as disloyal or invite sharp backlash. But this fear,… →
-
Why Most Founders Build the Wrong Company
The GTM Podcast is available on any major directory, including: Apple Podcasts Spotify YouTube Lou Shipley (three-time CEO, Harvard Business School professor, and author of Unlikely Entrepreneurs) joins GTMnow to break down why most founders struggle to turn good ideas into great companies. Lou has led companies through acquisitions, teaches sales and go-to-market at Harvard,… →
-
The Safety and Efficacy of Absnow Fully Biodegradable Atrial Septal Defect Occluder: A Prospective, Single-Center Phase III Clinical Trial
CONCLUSION: This study further confirmed the short-to-mid-term safety and acceptable efficacy of the Absnow fully biodegradable atrial septal occluder based on a 4-year follow-up. The late-occurring residual shunts with device degradation have an important impact on its long-term efficacy. →
-
Probiotic Supplementation Reduces RRTIs and Enhances Gut Microbial and Immunity in Children: A Randomized Controlled Trial
Recurrent respiratory tract infections (RRTIs) are a major cause of morbidity in children, and strain-defined probiotics have been proposed as a supportive preventive strategy, although clinical evidence remains limited. In this randomized, double-blind, placebo-controlled trial, 120 children diagnosed with RRTIs received either Bifidobacterium animalis subsp. lactis XLTG11 and Lactiplantibacillus plantarum CCFM8661 or a matched placebo… →
-
Effect of Bioptron light therapy on dryness of eyes in postmenopausal women: a randomized controlled trial
To examine the short-term therapeutic effects of Bioptron light therapy (BLT) on dry eye disease (DED) in postmenopausal women. Sixty postmenopausal women diagnosed with DED, aged 50-62 years with a body mass index ≤ 30 kg/m², were randomly assigned to two equal groups. The Bioptron group (n = 30) received BLT for 10 min, twice… →
-
Safety and tolerability of avacincaptad pegol in combination with ranibizumab in treatment-naïve patients with neovascular age-related macular degeneration: results from a phase 1 and phase 2a study
CONCLUSIONS: Coadministration of ACP and ranibizumab in treatment-naïve patients with nAMD was well tolerated across different dosing regimens with no new safety issues based on results from two independent studies. →
